1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Merck Reports Good News/Bad News In Latest Keytruda Readouts

 
• By Joseph Haas

With successful Phase III data, Merck will look to add biliary tract cancer to Keytruda’s label, but it will discontinue a Phase III study in prostate cancer after an interim analysis showed no survival benefit.

Good & Bad
Merck's Keytruda showed benefit in biliary cancer, but not prostate • Source: Shutterstock

Results from Merck & Co., Inc.’s numerous combination trials featuring anti-PD-1 blockbuster Keytruda (pembrolizumab) keep pouring in, with the pharma announcing success in biliary tract cancer (BTC), while revealing plans to end a futile study in metastatic prostate cancer on 25 January. The New Jersey-headquartered firm said it will share the BTC dataset with regulators in hopes of adding yet another indication to Keytruda’s label.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.

More from R&D

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Could There Be A Cure For Cardiometabolic Disease? Novo Nordisk Foundation Wants To Help Academics Find Out

 
• By Andrew McConaghie

The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.